Treatment results of high-risk defined by NCI criteria childhood acute lymphoblastic leukemia in AIEOP-ALL studies over two decades.

被引：0
|
作者：
Aricò, M
Conter, V
Valsecchi, MG
Rizzari, C
Barisone, E
Messina, C
Lo Nigro, L
Pinta, MF
De Rossi, G
Pession, A
Testi, AM
Santoro, N
Di Tullio, MT
Micalizzi, C
Favre, C
Lippi, A
Rondelli, R
Silvestri, D
Biondi, A
Basso, G
Masera, G
机构：
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2001
引用
收藏
页码：464A / 465A
页数：2
相关论文
共 50 条
  • [31] INTENSIVE ALTERNATING DRUG PAIRS FOR TREATMENT OF HIGH-RISK CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA - A PEDIATRIC ONCOLOGY GROUP PILOT-STUDY
    LAUER, SJ
    CAMITTA, BM
    LEVENTHAL, BG
    MAHONEY, DH
    SHUSTER, JJ
    ADAIR, S
    CASPER, JT
    CIVIN, CI
    GRAHAM, M
    KIEFER, G
    PULLEN, J
    STEUBER, CP
    KAMEN, B
    CANCER, 1993, 71 (09) : 2854 - 2861
  • [32] Impact of Age and Treatment Group in Childhood High Hyperdiploid Low Risk B-Cell Acute Lymphoblastic Leukemia (ALL): Results of the CLG-EORTC 58951 Study
    Clement, Laura
    Suciu, Stefan
    Luquet, Isabelle
    Ferster, Alina
    Yakouben, Karima
    Uytterbroeck, Anne
    Paillard, Catherine
    Sirvent, Nicolas
    Costa, Vitor
    De Moerloose, Barbara
    Mazingue, Francoise
    Plouvier, Emmanuel
    Munzer, Martine
    Poiree, Maryline
    Minckes, Odile
    Millot, Frederic
    Plantaz, Dominique
    Piette, Caroline
    Speleman, Frank
    Cave, Helene
    VanderWerff-TenBossch, Jutte
    Rohrlich, Pierre Simon
    Bertrand, Yves
    Benoit, Yves
    Plat, Genevieve
    BLOOD, 2016, 128 (22)
  • [33] Genome-Wide Association Study (GWAS) of High-Risk Minimal Residual Disease and Relapse in B-Cell Acute Lymphoblastic Leukemia on Trial AIEOP-BFM ALL 2000
    Hinze, Laura
    Junk, Stefanie V.
    Klein, Norman
    Moricke, Anja
    Cario, Gunnar
    Kratz, Christian P.
    Houlston, Richard S.
    Bartam, Claus R.
    Koehler, Rolf
    Zimmermann, Martin
    Schrappe, Martin
    Stanulla, Martin
    BLOOD, 2017, 130
  • [34] Outcome of children with high-risk acute lymphoblastic leukemia (HR-ALL): Nordic results on an intensive regimen with restricted central nervous system irradiation
    Saarinen-Pihkala, UM
    Gustafsson, G
    Carlsen, N
    Flaegstad, T
    Forestier, E
    Glomstein, A
    Kristinsson, J
    Lanning, M
    Schroeder, H
    Mellander, L
    PEDIATRIC BLOOD & CANCER, 2004, 42 (01) : 8 - 23
  • [35] Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II
    Aricò, M
    Valsecchi, MG
    Conter, V
    Rizzari, C
    Pession, A
    Messina, C
    Barisone, E
    Poggi, V
    De Rossi, G
    Locatelli, F
    Micalizzi, MC
    Basso, G
    Masera, G
    BLOOD, 2002, 100 (02) : 420 - 426
  • [36] Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000)
    Schrappe, Martin
    Bleckmann, Kirsten
    Zimmermann, Martin
    Biondi, Andrea
    Moericke, Anja
    Locatelli, Franco
    Cario, Gunnar
    Rizzari, Carmelo
    Attarbaschi, Andishe
    Valsecchi, Maria Grazia
    Bartram, Claus R.
    Barisone, Elena
    Niggli, Felix
    Niemeyer, Charlotte
    Testi, Anna Maria
    Mann, Georg
    Ziino, Ottavio
    Schafer, Beat
    Panzer-Gruemayer, Renate
    Beier, Rita
    Parasole, Rosanna
    Goehring, Gudrun
    Ludwig, Wolf-Dieter
    Casale, Fiorina
    Schlegel, Paul-Gerhardt
    Basso, Giuseppe
    Conter, Valentino
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (03) : 244 - +
  • [37] Bone marrow transplantation versus chemotherapy in the treatment of very high-risk childhood acute lymphoblastic leukemia in first remission: results from Medical Research Council UKALL X and XI
    Wheeler, KA
    Richards, SM
    Bailey, CC
    Gibson, B
    Hann, IM
    Hill, FGH
    Chessells, JM
    BLOOD, 2000, 96 (07) : 2412 - 2418
  • [38] TREATMENT OF MEDIUM-RISK AND HIGH-RISK (M-H R) ACUTE LYMPHOBLASTIC-LEUKEMIA (ALL) WITH OR WITHOUT CRANIAL RADIOTHERAPY (RXT) RESULTS OF A RANDOMIZED TRIAL (EORTC NR 58832)
    BENOIT, Y
    BOILLETOT, A
    FRANCOTTE, N
    HOYOUX, C
    MARGUERITTE, G
    PHILIPPE, N
    SOUILLET, G
    THYSS, A
    SOLBU, G
    SUCIU, S
    OTTEN, J
    MEDICAL AND PEDIATRIC ONCOLOGY, 1988, 16 (06): : 388 - 388
  • [39] Long-Term Results of the Risk-Stratified Treatment of Childhood Acute Lymphoblastic Leukemia in China: A Retrospective Study of the SCMC-ALL-2005 Protocol
    Cai, J.
    Shen, S.
    Chen, J.
    Xue, H.
    Pan, C.
    Gao, Y.
    Tang, Y.
    Wang, J.
    Li, B.
    Wang, X.
    Chen, J.
    Gu, L.
    Tang, J.
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S105 - S105
  • [40] No Benefit of High Dose Methotrexate (HD-MTX) in Intermediate Risk Childhood Acute Lymphoblastic Leukemia (ALL): Results of 2 Randomised Multicenter Trials in Russia
    Karachunskiy, A.
    Ponomareva, N.
    Roumiantseva, J.
    Aleynikova, O.
    Arakaev, O.
    Litvinov, D.
    Karelin, A.
    Boychenko, E.
    Sharapova, G.
    Lagoyko, S.
    Bydanov, O.
    Henze, G.
    PEDIATRIC BLOOD & CANCER, 2016, 63 : S27 - S27
12345